If you have been reading about immunomodulator and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-12. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Dithiocarbamate fungicides are also associated with increased PD risk. Organochlorine pesticides such as DDT were banned in the United States in 1972; pesticides such as dieldrin are also associated with increased PD risk and still may be used elsewhere. Organophosphates such as chlorpyrifos and diazinon are linked with increased PD risk, and have been banned in the European Union. Concerns have been raised about pyrethroid pesticides such as cypermethrin, which are globally used both agriculturally and domestically, often as a replacement for organophosphates. Rural living, well-drinking, and farming are all associated with Parkinson's, which may be partly explained by local pesticide exposure through direct contact and contaminated air or ground water. These factors are pertinent to many communities, including Brazilian and South Asian populations. Organochlorine pesticides continue to be associated with increased risk for Parkinson's disease in Asia. In France, Parkinson's disease was officially recognized as an occupational disease of agricultural workers in 2012. A Decree acknowledging a causal link between pesticides and PD entered into force on 7 May 2013. In March 2024, Germany formally adopted a similar recommendation for the occupational disease category of "Parkinson's Disease caused by pesticides", no longer using the term "idiopathic" PD. Since 2019, the Movement Disorder Society (MDS) has included "regular pesticide exposure" as a risk factor in the MDS research criteria for prodromal Parkinson's disease. Many pesticides are mitochondrial toxins.
==== Mexico's economy ==== Over the past few decades, drug cartels have become integrated into Mexico's economy. Approximately 500 cities are directly engaged in drug trafficking and nearly 450,000 people are employed by drug cartels. Additionally, the livelihood of 3.2 million people is dependent on the drug cartels. Between local and international sales, such as to Europe and the United States, drug cartels in Mexico see a $25–30 bn yearly profit, a great deal of which circulates through international banks such as HSBC. Drug cartels are fundamental in local economics. A percentage of the profits seen from the trade are invested in the local community. Such profits contribute to the education and healthcare of the community. While these cartels bring violence and hazards into communities, they create jobs and provide income for its many members.
Complexes of macromolecules occur ubiquitously in nature, where they are involved in the construction of viruses and all living cells. In addition, they play fundamental roles in all basic life processes (protein translation, cell division, vesicle trafficking, intra- and inter-cellular exchange of material between compartments, etc.). In each of these roles, complex mixtures of become organized in specific structural and spatial ways. While the individual macromolecules are held together by a combination of covalent bonds and intramolecular non-covalent forces (i.e., associations between parts within each molecule, via charge-charge interactions, van der Waals forces, and dipole–dipole interactions such as hydrogen bonds), by definition MAs themselves are held together solely via the noncovalent forces, except now exerted between molecules (i.e., intermolecular interactions).
When not flying, bats hang upside down from their feet, a posture known as roosting. Most megabats roost with the head tucked towards the belly, whereas most microbats roost with the neck curled towards the back. This difference is due to the structure of the cervical or neck vertebrae in the two groups, which are clearly distinct. Tendons allow bats to hang from a roost with no effort, which is needed to release. Bats are more awkward when crawling on the ground, though a few species, such as the New Zealand lesser short-tailed bat (Mystacina tuberculata) and the common vampire bat (Desmodus rotundus), are quite agile. These species move their limbs one after the other, but vampire bats accelerate by bounding, the folded-up wings being used to propel them forward. Vampire bats likely evolved these gaits to stalk their hosts, while short-tailed bats took to the ground due to a lack of competition from other mammals. Terrestrial locomotion does not appear to affect their ability to fly.
Sources: en.wikipedia.org
== Further reading == Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. (October 2023). "Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis". The New England Journal of Medicine. 389 (17): 1579–1589. doi:10.1056/NEJMoa2301333. hdl:1854/LU-01JMVNTYQXH55FHHB47BSMETXX. PMID 37888917. Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, et al. (August 2024). "Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials". Lancet. 404 (10451): 445–460. doi:10.1016/S0140-6736(24)01203-0. PMID 39067461.
And although the proposal was heard and notified to Torre Tagle, no one in the government of San Martín responded to this request. Which shows that for the Creole oligarchy in the Trujillo Intendancy there was a lack of interest towards the indigenous political Society, for which the successors of the Incas were not considered for any alternative government. Leaving a tacit glimpse that the liberal movement of San Martin could end in a monarchical government, or perhaps a republican one, but in either case, it would be led by the Criollo elite and not by indigenous people, no matter how stately and regal lineage they could make ostentation.
Australasian Association of Clinical Geneticists Australasian Society of Diagnostic Genomics Australasian Society of Genetic Counsellors Australasian Society for Inborn Errors of Metabolism Australasian Cancer Genetics Group
== Medical uses == LAAM is indicated as a second-line treatment for the treatment and management of opioid dependence if patients fail to respond to drugs like methadone or buprenorphine. LAAM is used as an oral solution of LAAM hydrochloride at a concentration of 10 mg/mL in bottles of 120 and 500 mL under the brand name Orlaam. The first dose of LAAM for patients who have not started treatment with methadone is 20–40 mg. The first dose for patients who have been receiving methadone will be a little higher than the amount of methadone that was being taken every day, but not more than 120 mg. Afterwards, the dosage may be adjusted as needed. Unlike methadone, which requires daily administration, LAAM is administered two to three times a week.
==== Mechanism of action ==== Xanomeline modulates certain dopaminergic and glutamatergic circuits in the brain that can provide therapeutic benefits in patients suffering from neuropsychiatric and neurological diseases such as schizophrenia and Alzheimer's disease through stimulation primarily of central M1 and M4 muscarinic receptor subtypes. Muscarinic M1 and M4 receptors have been shown in preclinical studies to be expressed in areas important for dopamine and glutamate neural circuit regulation (e.g. frontal cortex and dorsal and ventral striatum). Xanomeline has shown antipsychotic-like effects in various preclinical behavioral models, such as attenuation of amphetamine-induced locomotor hyperactivity, effects that are dependent on M1 and M4 receptor activation.
Sources: en.wikipedia.org
=== Cancer === Abdominal obesity has been associated with an increased risk of several cancers, particularly malignancies of the digestive system. These include colorectal, pancreatic, and esophageal cancers. These associations often remain even after adjustment for overall body mass index, which suggests that abdominal fat distribution is an independent risk factor. In women, abdominal obesity has also been linked to higher rates of breast cancer in both the pre- and post-menopausal periods, beyond the effects of general obesity.
== Additives == Mobile phase pH and electrostatic interactions, as well as analyte polarity, are regulated by the addition of ionic additives. These additives improve separation efficiency, including more symmetric peaks, less peak tailing, and better recovery from the stationary phase. Ammonium acetate and ammonium formate are commonly used, as they have good solubility in high organic. When considering additive addition, compatibility with detectors is important to consider. HILIC is often used with a mass spectrometry (MS), which cannot handle non-volatile salts like sodium perchlorate, which may suppress ion signal in the instrument, though it may increase mobile phase polarity and assist with elution in HILIC.
That said, Moroccan-Israeli mafia clans are known for having collaborated closely together with the Mocro Maffia in the Netherlands and Belgium, especially in the worldwide distribution of synthetic drugs such as MDMA. This is mostly due to the fact that the Netherlands is the largest producer of MDMA and amphetamines in the world.
== Research == Friedler's research is in chemical biology, peptide chemistry, protein chemistry, biophysical chemistry, and medicinal chemistry. It focuses on the use of peptides and peptide-based methods to study and inhibit protein–protein interactions, with a particular focus on interactions involving intrinsically disordered protein regions. His work has used synthetic, structural and biophysical approaches to investigate the molecular basis of these interactions and peptide-based methods to modulate them. His research has examined interactions involving the tumour-suppressor protein p53, including its interactions with MDM2. His work has also addressed proteins associated with apoptosis and cancer-related signalling pathways. He has also studied interactions among HIV-1 proteins, including integrase, Rev, Vif, and Tat, and peptide-based approaches to influencing viral protein interactions. A particular focus of Friedler's research has been the use of intrinsically disordered proteins as therapeutic targets and as sources for peptide inhibitors of protein–protein interactions. Other work by Friedler and his collaborators has addressed protein oligomerisation and protein aggregation, including amyloid formation and the aggregation of proteins associated with cancer and neurodegenerative disease. His more recent research has also included methods for synthesizing multiphosphorylated peptides and protein-interaction-based biosensors.
=== Withdrawal === Users of hydromorphone may experience painful symptoms if the drug is suspended. Some people cannot tolerate the symptoms, which results in continuous drug use. Symptoms of opioid withdrawal are not easy to decipher, as there are differences between drug-seeking behaviors and true withdrawal effects. Symptoms associated with hydromorphone withdrawal include:
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.